Zidesamtinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Zidesamtinib. Educational only — not medical advice.
Labeled uses
JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor [see Dosage and Administration (2.1 ), Clinical Studies (14.1 )] .
Source: FDA labeling via NIH DailyMed (set 3760e421…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.